Maternal antiretroviral use during pregnancy and infant congenital anomalies: The NISDI perinatal study

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 2, 2010, Pages 176-185

  Joao, Esau C ^a   Calvet, Guilherme A ^a   Krauss, Margot R ^b   Freimanis Hance, Laura ^b   Ortiz, Javier ^c   Ivalo, Silvina A ^d   Pierre, Russell ^e   Reyes, Mary ^f   Heather Watts, D ^g   Read, Jennifer S ^g  

^a HOSPITAL DOS SERVIDORES DO ESTADO   (Brazil)

^b WESTAT   (United States)

^c INSTITUTO NACIONAL DE PERINATOLOGÍA   (Mexico)

^d HOSPITAL RAMOS MEJÍA   (Argentina)

^e UNIVERSITY OF THE WEST INDIES   (Jamaica)

^f Universidad Nacional Mayor de San Marcos   (Peru)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Antiretrovirals; Congenital anomalies; HIV 1; Pregnancy

Indexed keywords

ANTIRETROVIRUS AGENT; NUCLEOTIDE DERIVATIVE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ANENCEPHALUS; ARTICLE; CHILD DEATH; CHORDEE; CHROMOSOME ABERRATION; CLEFT PALATE; COHORT ANALYSIS; CONGENITAL HIP DISLOCATION; CONGENITAL MALFORMATION; CORPUS CALLOSUM AGENESIS; CRYPTORCHISM; DELIVERY; DISEASE ASSOCIATION; ECTOPIC KIDNEY; FEMALE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HEART ARRHYTHMIA; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HEMANGIOMA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIP DYSPLASIA; HIRSCHSPRUNG DISEASE; HORNER SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYDROCELE; HYDRONEPHROSIS; HYDROURETER; HYPOSPADIAS; INFANT; INGUINAL HERNIA; KYPHOSCOLIOSIS; LIVE BIRTH; MAJOR CLINICAL STUDY; MATERNAL CARE; MENKES SYNDROME; MICROCEPHALY; MICROPHTHALMIA; MUSCULOSKELETAL SYSTEM MALFORMATION; NEVUS; NEVUS FLAMMEUS; OMPHALOCELE; PATENT DUCTUS ARTERIOSUS; PATENT FORAMEN OVALE; PERINATAL CARE; PERINATAL DRUG EXPOSURE; PES EQUINOVARUS; PLAGIOCEPHALY; POLYDACTYLY; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY ARTERY STENOSIS; REGISTER; SECOND TRIMESTER PREGNANCY; SKIN APLASIA; STILLBIRTH; SYNDACTYLY; UMBILICAL HERNIA; VALGUS DEFORMITY; VALGUS KNEE; VULVA SYNECHIA;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTERS;

EID: 75649133884     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181c5c81f     Document Type: Article

References (34)

1. Szyld EG, Warley EM, Freimanis L, et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS. 2006;20:2345-2353.
2. Kourtis AP, Schmid CH, Jamieson DJ, et al. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS. 2007;21:607-615.
3. Tuomala RE, Watts DH, Li D, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005;38:449-473.
4. Cotter AM, Garcia AG, Duthely ML, et al. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis. 2006;193:1195-1201.
5. Thorne C, Newell ML. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern? Drug Saf. 2007;30: 203-213.
6. Maciel ELN, Goncalves EP, Alvarenga VA, et al. Perfil epidemiológico das malformaxcões congênitas no munićipio de Vitória-ES. Cad Saude Coletiva (Rio de Janeiro). 2006;14:507-518.
7. Secretaria Municipal de Saúde. Gerência de Informaxcões Epidemiológ-icas. Série Histórica dos Nascimentos na Cidade do Rio de Janeiro-1993-2005. Available at: http://www.saude.rio.rj.gov.br/media/sinasc9305novo- caracternv.pdf. Accessed July 20, 2009.
8. de Castro MLS, da Cunha CJ, Moreira PB, et al. Frequência das malformaxcões múltiplas em recém-nascidos na Cidade de Pelotas, Rio Grande do Sul, Brasil, e fatores socio-demográficos associados. Cad Saude Publica (Rio de Janeiro). 2006;22:1009-1015.
9. da Silva Costa CM, da Gama SGN, do Carmo Leal M. Congenital malformations in Rio de Janeiro, Brazil: prevalence and associated factors. Cad Saude Publica (Rio de Janeiro). 2006;22:2423-2431.
10. Castilla EE, Orioli IM. ECLAMC: the Latin-American collaborative study of congenital malformations. Community Genet. 2004;7:76-94.
11. Nazer J, Cifuentes L, Aguila A, et al. Edad materna y malformaciones congenitas. Un registro de 35 anos: 1970-2005. Rev Med Chile. 2007; 135:1463-1469.
12. Read JS, Cahn P, Losso M, et al. Management of human immunodeficiency virus-infected pregnant women at Latin American and Caribbean sites. Obstet Gynecol. 2007;109:1358-1367
13. Centers for Diseases Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41(RR-17):1-19.
14. Ballard JL, Khoury JC, Wedig K, et al. New Ballard score, expanded to include extremely premature infants. J Pediatr. 1991;119: 417-423.
15. Dubowitz LM, Dubowitz V, Goldberg C. Clinical assessment of gestational age in the newborn infant. J Pediatr. 1970;77:1-10.
16. Capurro H, Konichezky S, Fonseca D, et al. A simplified method for diagnosis of gestational age in the newborn infant. J Pediatr. 1978;93: 120-122.
17. Unidad Coordinadora Ejecutora De VIH/SIDA/ETS; Argentina. Recomendaciones Para La Prevencion De La Transmision Perinatal Del VIH, noviembre 2001. Available at: http://www.msal.gov.ar/htm/ site/promin/UCMISALUD/publicaciones/ pdf/08-HIV.pdf. Accessed July 20, 2009.
18. Recomendaxcões para Profilaxia da Transmissão Vertical do HIVe Terapia Anti-Retroviral em Gestantes; Ministério da Saúde, Secretaria de Vigilância em Saúde, Programa Nacional de DST e AIDS, 2006. Available at: http:// www.aids.gov.br/data/documents/storedDocuments/ %7BB8EF5DAF-23AE-4891-AD36-1903553A3174%7D/%7B8B7D14E5-85F1-482A-ABDA- 11088D087EE9%7D/ConsensoGestantes%202006-%FAltima%20vers% E3o-27julho2006.pdf. Accessed July 20, 2009.
19. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2008. Available at: http://www.apregistry.com/forms/ exec-summary.pdf. Accessed July 20, 2009.
20. Centers for Disease Control and Prevention. Metropolitan Atlanta Congenital Defects Program. Surveillance procedure manual and guide to computerized anomaly record. Atlanta (GA): US Department of Health and Human Services, Public Health Service; 1998. Available at: http://www.cdc.gov/ncbddd/ bd/documents/MACDPcode%200807.pdf. Accessed July 20, 2009.
21. Scheuerle A, Tilson H. Birth defect classification by organ system: a novel approach to heighten teratogenic signalling in a pregnancy registry. Pharmacoepidemiol Drug Saf. 2002;11:465-475.
22. Duran A, Ivalo S, Hakim A, et al. Prevention of mother to child HIV transmission. Medicina (B. Aires) 2006;66:24-30.
23. Calvet GA, Joao EC, Nielsen-Saines K, et al. Trends in a cohort of HIV-infected pregnant women in Rio de Janeiro, 1996-2004. Rev Bras Epidemiol. 2007;10:323-337.
24. Moreira LMA, Dias AL, Ribeiro HBS, et al. Associaxcão entre o use de abortifacientes e defeitos congênitos. Rev Bras Ginecol Obstet. 2001;23: 517-551.
25. Watts DH, Li D, Handelsman E, et al. Assessment of birth defects according to maternal therapy among infants in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr. 2007;44: 299-305.
26. Townsend CL, Willey BA, Cortina-Borja M, et al. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990 to 2007. AIDS. 2009;23:519-524.
27. Patel D, Thorne C, Fiore S, et al. Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women? J Acquir Immune Defic Syndr. 2005;40:116-118.
28. Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343: 1608-1614.
29. Bailey LB, Berry RJ. Folic acid supplementation and the occurrence of congenital heart defects, orofacial clefts, multiple births, and miscarriage. Am J Clin Nutr. 2005;81:S1213-S1217.
30. Czeizel AE. Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation. Am J Med Genet. 1996; 62:179-183.
31. Jungmann EM, Mercey D, DeRuiter A, et al. Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities? Sex Transm Infect. 2001;77:441-443.
32. Castilla EE, Orioli IM, Lopez-Camelo JS, et al. Preliminary data on changes in neural tube defect prevalence rates after folic acid fortification in South America. Am J Med Genet A. 2003;123A:123-128.
33. Gadow EC, Castilla EE, Lopez Camelo J, et al. Stillbirth rate and associated risk factors among 869,750 Latin American hospital births: 1982-1986. Int J Gynaecol Obstet. 1991;35:209-214.
34. Massad LS, Springer G, Jacobson L, et al. Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS. 2004;23;18:281-286.